Biohaven Ltd. (BHVN) |
| 14.72 -0.22 (-1.47%) 07-15 12:15 |
| Open: | 14.95 |
| High: | 14.95 |
| Low: | 14.62 |
| Volume: | 289,856 |
| Market Cap: | 1,558(M) |
| PE Ratio: | -2.6 |
| Exchange: | New York Stock Exchange |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 20.18 |
| Resistance 1: | 17.28 |
| Pivot price: | 15.54 |
| Support 1: | 13.20 |
| Support 2: | 10.68 |
| 52w High: | 18.566 |
| 52w Low: | 7.48 |
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
Financials
| EPS | -5.570 |
| Book Value | 0.860 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -83.4 |
| Return on Equity (ttm) | -333.0 |
Company news
Tue, 14 Jul 2026
Price to earnings forward of Biohaven Ltd. – BOATS:BHVN - TradingView
Mon, 13 Jul 2026
Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk (NYSE:BHVN) - Seeking Alpha
Sat, 11 Jul 2026
Biohaven (BHVN) Advances Key Trials Following Pipeline Progress While Valuation Still Looks Pricey - Sahm
Fri, 10 Jul 2026
BHVN News | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Thu, 09 Jul 2026
Biohaven (NYSE: BHVN) shifts CSO to innovation role, promotes discovery head - Stock Titan
Thu, 09 Jul 2026
Biohaven Announces Scientific Leadership Transitions - PR Newswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
